KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non Operating Income: 2010-2024

Historic Other Non Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $16.2 million.

  • Supernus Pharmaceuticals' Other Non Operating Income fell 44.44% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 22.66%. This contributed to the annual value of $16.2 million for FY2024, which is 55.02% up from last year.
  • Supernus Pharmaceuticals' Other Non Operating Income amounted to $16.2 million in FY2024, which was up 55.02% from $10.5 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Non Operating Income peaked at $21.7 million during FY2022, and registered a low of -$12.9 million during FY2021.
  • For the 3-year period, Supernus Pharmaceuticals' Other Non Operating Income averaged around $16.1 million, with its median value being $16.2 million (2024).
  • In the last 5 years, Supernus Pharmaceuticals' Other Non Operating Income plummeted by 168.72% in 2021 and then soared by 268.73% in 2022.
  • Supernus Pharmaceuticals' Other Non Operating Income (Yearly) stood at $18.7 million in 2020, then slumped by 168.72% to -$12.9 million in 2021, then skyrocketed by 268.73% to $21.7 million in 2022, then tumbled by 51.81% to $10.5 million in 2023, then surged by 55.02% to $16.2 million in 2024.